Fig. 1. BP-1-102 decreased AAA formation and progression.

a Eight-week-old male ApoE^−/− mice were administrated with AngII (1.44 mg/kg/day) and DSMO-PBS (AngII⁺ group) or AngII (1.44 mg/kg/day) and BP-1-102 (5 mg/kg) (AngII⁺ BP-1-102⁺ group) at indicated time points. Saline administrated was used as control group (mock) (left). Representative images of AAA at each time point were presented. AngII⁺ BP-1-102⁺ group (AngII⁺BP⁺, lower panel) showed less severity of AAA compared with AngII⁺ group (upper panel) at each time point. Arrows indicate typical AAA. b The maximum aortic diameter at the infra-diaphragm was measured. The AngII⁺ BP-1-102⁺ group (AngII⁺BP⁺, blue dots) showed reduced aortic diameter comparing with AngII⁺ (red dots) at each time point (day 7, day 14, and day 28). The results were presented as mean ± standard deviation (SD). n = 8. *P < 0.01 vs. AngII⁺ group (two-way ANOVA followed by Tukey’s test). NS indicates non-significant differences compared with AngII⁺ group. c The incidence of AAA was evaluated on day 28. The AngII⁺ BP-1-102⁺ group (blue column) showed reduced incidence of AAA compared with AngII⁺ group (red column). n = 8. *P < 0.01 vs. AngII⁺ group (chi‐square test). NS indicates non-significant differences compared with AngII⁺ group.